arrow
N

Norbert Ndjeka

bringbpalme (bb) trial
H指数:26
被引数:3,384

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of linezolid interruption and rechallenge with clinical outcomes in patients with rifampicin-resistant tuberculosis in South Africa, 2018–22: an observational cohort study

利奈唑胺中断和再挑战与南非利福平耐药结核病患者临床结局的关联(2018–2022年):一项观察性队列研究

2026-03-160
OAAI
When are uncontrolled trials in TB scientifically and ethically justified: Borrowing wisdom from early AIDS clinical trials

无对照试验在结核病领域何时具有科学和伦理上的合理性:借鉴早期艾滋病临床试验的智慧

2026-03-130
OA
Treatment Outcomes and Drug-Related Adverse Events Across Four Short-Course RR-TB Regimens in South Africa: A Retrospective Analysis

治疗结局和药物相关不良事件在南非四种短程RR-TB方案中的比较:一项回顾性分析

2026-02-080
OAAI
Climate change and tuberculosis: an analytical framework

气候变化与结核病:一个分析框架

2025-10-300
PRE
The effectiveness, cost-effectiveness, budget impact, and return on investment of scaling up tuberculosis screening and preventive treatment in Brazil, Georgia, Kenya, and South Africa: a modelling study

扩大巴西、格鲁吉亚、肯尼亚和南非的结核病筛查和预防性治疗的有效性、成本效益、预算影响和投资回报:一项模型研究

2025-10-150
OAAI
Target regimen profiles for tuberculosis treatment

结核病治疗的目标方案概况

2024-08-011
OAAI
Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort Study

在南非使用包含利奈唑胺或乙硫胺酰胺的全口服9个月方案治疗耐多药或耐利福平结核病: 一项回顾性队列研究

2024-03-252
OAAI
The 1/4/6x24 campaign to cure tuberculosis quickly

1/4/6x24快速治愈结核病的运动

2023-01-109
PRE
Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis

南非耐多药结核病患者治疗后贝达奎兰的安全性、有效性、利用率和耐药性的出现: 一项回顾性队列分析

2022-11-2120
OAAI
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study
2022-07-0139
OAAI
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study
2022-04-0166
OAAI